Safety and immunogenicity of radiation-attenuated PfSPZ vaccine in equatoguinean infants, children, and adults

Jongo, S. A. and Urbano Nsue Ndong Nchama, V. and Church, L. W. P. and Olotu, A. and Manock, S. R. and Schindler, T. and Mtoro, A. and Kc, N. and Devinsky, O. and Zan, E. and Hamad, A. and Nyakarungu, E. and Mpina, M. and Deal, A. and Bijeri, J. R. and Ondo Mangue, M. E. and Ntutumu Pasialo, B. E. and Nguema, G. N. and Rivas, M. R. and Chemba, M. and Ramadhani, K. K. and James, E. R. and Stabler, T. C. and Abebe, Y. and Riyahi, P. and Saverino, E. S. and Sax, J. and Hosch, S. and Tumbo, A. and Gondwe, L. and Segura, J. L. and Falla, C. C. and Phiri, W. P. and Hergott, D. E. B. and García, G. A. and Maas, C. and Murshedkar, T. and Billingsley, P. F. and Tanner, M. and Ayekaba, M. O. and Sim, B. K. L. and Daubenberger, C. and Richie, T. L. and Abdulla, S. and Hoffman, S. L.. (2023) Safety and immunogenicity of radiation-attenuated PfSPZ vaccine in equatoguinean infants, children, and adults. The American journal of tropical medicine and hygiene, 109 (1). pp. 138-146.

PDF - Published Version
Available under License CC BY (Attribution).
739Kb

Official URL: https://edoc.unibas.ch/95314/

Downloads: Statistics Overview

Abstract

The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults /= 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1-5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.

Faculties and Departments:	09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Clinical Immunology (Daubenberger) 09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Health Interventions > Malaria Interventions (Lengeler) 09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Swiss Centre for International Health (SCIH) > Systems Performance and Monitoring (Pham-Tan)
UniBasel Contributors:	Schindler, Tobias and Mpina, Maximillian and Deal, Anna and Hosch, Salome and Tumbo, Anneth and Segura, Luis and Tanner, Marcel and Daubenberger, Claudia
Item Type:	Article, refereed
Article Subtype:	Research Article
ISSN:	0002-9637
Note:	Publication type according to Uni Basel Research Database: Journal article
Language:	English
Related URLs:	Document
Identification Number:	doi: 10.4269/ajtmh.22-0773 pmid: 37160281
edoc DOI:	10.5451/unibas-ep95314
Last Modified:	24 Oct 2023 06:45
Deposited On:	24 Oct 2023 06:45

Repository Staff Only: item control page